What Is 7-OH? The Kratom Alkaloid Massachusetts Named

What is 7-OH? It is shorthand for 7-hydroxymitragynine, one of the dozens of alkaloids in the kratom leaf and the one doing most of the work in every regulatory document written about this plant in 2026. It sits in natural leaf at trace levels, forms in the body when mitragynine is metabolised, and can be manufactured and concentrated far past anything the plant produces. That gap is the whole regulatory story, and the Massachusetts order published on 13 August 2026 answers it in a way no other state has.

If you read labels, buy extract, or sell it, the useful thing about that order is not that another state moved. It is how the state wrote the rule.

What is 7-OH, exactly?

7-hydroxymitragynine is a single molecule with the formula C23H30N2O5, catalogued by the National Library of Medicine as PubChem compound 44301524. Mitragynine, the alkaloid that actually defines kratom, is C23H30N2O4. Count the oxygens. The entire difference between the leaf's headline compound and the one every regulator in the country is chasing is a single oxygen atom in a single position, which is also why one chemical step converts one into the other.

That step is not confined to a factory. The National Institute on Drug Abuse writes in its research overview of kratom that mitragynine "is found in kratom leaves and breaks down into 7-OH in the body when digested". DEA says the same at 91 FR 40917: 7-OH "also exists as an active oxidized metabolite of mitragynine in vivo". Anyone who has taken plain leaf has been exposed to 7-OH formed internally. The line between leaf and concentrate is about how much arrives and how fast.

That NIDA page is also where the federal baseline sits, and it needs a date on it. NIDA records that the Drug Enforcement Administration has listed kratom as a drug of concern, though kratom and kratom compounds are not listed on the United States schedule of controlled substances. The page predates the July 2026 filings below.

The hydroxyl group at position 7 gives the molecule a stronger grip on the mu-opioid receptor, the one morphine and oxycodone act on. FDA states that 7-OH "demonstrates substantially greater mu-opioid receptor potency" than mitragynine, and greater than classical opioids including morphine. That sentence sits on the FDA's kratom page and is worth reading in context. FDA attaches no multiple to it, so neither do we. Among the effects DEA associates with 7-OH are respiratory depression, tolerance and dependence.

One correction before anyone builds a claim on it. DEA states that "the chemical structures of synthetic and naturally occurring 7-hydroxymitragynine are identical", and that the "intrinsic pharmacological profile, receptor affinity, and mechanism of action ... remain unchanged regardless of its source". Potency is a function of concentration and dose, not of origin.

How much 7-OH is actually in kratom leaf?

Very little. FDA describes 7-OH as a naturally occurring alkaloid in the kratom plant but "only a minor constituent that comprises less than 2% of the total alkaloid content in natural kratom leaves." That is the published ceiling and the only sourced figure on leaf content. No published typical value below it turned up, so none is offered here.

Massachusetts says the same in its own words. The Department of Public Health's kratom page states that kratom plants contain naturally occurring compounds that affect the brain, "primarily mitragynine and trace amounts of 7-hydroxymitragynine (7-OH)". Trace. That is the state's word, on the state's own site, in the same month it moved to schedule the whole plant.

So the leaf is a mitragynine product with a rounding error of 7-OH in it, plus whatever the body makes afterwards. A concentrated 7-OH tablet takes the rounding error and makes it the product. DEA's fact sheet on kratom identifies mitragynine and 7-OH as its two major psychoactive ingredients.

The four compounds Massachusetts named

DPH writes that the compounds in kratom "can also be altered in a lab to create highly potent synthetic products that have more intense opioid-like effects," and then it names them: high amounts of 7-OH, plus mitragynine pseudoindoxyl (MP), dihydro-7-hydroxymitragynine (MGM-15) and 9-fluoro-7-hydroxymitragynine (MGM-16). Three of those four are not household names even inside this industry.

The MP entry deserves a second look. Mitragynine pseudoindoxyl is PubChem compound 44301701, molecular formula C23H30N2O5. Identical to 7-OH. Same atoms, same count, arranged differently, which makes the two isomers of each other.

That shared formula is a chemistry curiosity, not the reason MP goes unreported, and the version of this claim circulating in the trade has the mechanism wrong. Commercial alkaloid testing is normally a targeted panel: the laboratory quantifies a named list of compounds, usually mitragynine and 7-OH. Anything off that list is absent from the certificate whether or not it is in the bottle, isomer or not. MP is rarely on the list. Neither are MGM-15 and MGM-16. Ask a vendor which compounds the panel screened for, not what the mitragynine number was.

MGM-15 is 7-OH with two hydrogens added. MGM-16 is that same reduced structure with fluorine on it, which is why DEA writes it as 9-fluoro-dihydro-7-hydroxymitragynine. On those two, "designed molecule" is right: DEA records both were developed as potent opioid agonists in 2014. MP is not, and saying so is the less convenient version for a seller. DEA calls MP a chemical rearrangement product of 7-hydroxymitragynine, first isolated in 1974 as a metabolite from bio transformed mitragynine. It was found before it was made.

The federal approach: a number, and a carve-out

DEA announced the start of the temporary scheduling process under the Controlled Substances Act on 1 July 2026, and the notices were published in the Federal Register on 6 July 2026. There are two of them, not one. The first, at 91 FR 40917, covers 7-hydroxymitragynine above a specified threshold. The second, at 91 FR 40910, covers mitragynine pseudoindoxyl, MGM-15 and MGM-16, which is why the three names on the DPH page are familiar. The same day, HHS opened a comment period at 91 FR 41049 asking what concentration of 7-OH constitutes an imminent hazard. It closed on 31 July 2026 with 32,145 comments.

DEA said the temporary scheduling order itself "will be published in the Federal Register on or after August 5, 2026". The status box above records where that stood when we last updated this page.

Here is the number, because an article that tells you to look for a threshold and prints none is not much use. Under the notice of intent at 91 FR 40917, restated in the HHS request for information at 91 FR 41049, the scope reaches botanical material containing "more than 0.050 percentage of 7-hydroxymitragynine on a dry weight basis". It separately reaches material that has been "further processed to manufacture alternative dosage forms such as extracts, concentrates, processed edibles, or pressed pills" where 7-OH exceeds the same 0.050 percentage weight by weight, or where there is "greater than 1.00 milligram of 7-hydroxymitragynine in the article".

Read that second limb again, because it is where a familiar summary of the federal action falls apart. The threshold text names extracts, concentrates, processed edibles and pressed pills expressly. It applies a concentration test and a per-unit milligram test to both, and a small, strong unit can fail the milligram test on very little material. We have written on this blog before about 7-OH versus mitragynine and the federal filings, before the full threshold language was public. Where that piece and the Federal Register text differ, go with the Federal Register.

FDA summarised the actions on its 7-OH public health focus page, last updated 13 July 2026, and included one sentence the industry has quoted ever since: the agencies stated the actions "are intended to target concentrated and synthetic 7-OH products and are not intended to apply to natural kratom leaf containing only naturally occurring trace levels of 7-OH."

Read that as a design choice, not a favour. The federal drafting is built on a measurement: how much 7-OH is in the product, with everything above the line going into Schedule I and everything below it left alone. That targets the thing causing the harm rather than the category it arrived in, and it depends on laboratories, thresholds and sampling protocols, each of which is a place a rule can be contested.

Massachusetts did not draw that line

The instrument is 105 CMR 726.000, an emergency regulation published on 13 August 2026, taking effect on 28 August 2026, placing kratom in Schedule I under Massachusetts law for up to one year. The state's published summary of its scope is one phrase: all forms of kratom. The governor's announcement separately describes kratom as widely sold as powders, tablets, capsules, gummies and dissolvable strips, a description of the market rather than the order's coverage language.

Now note what the state has not announced. No 7-OH concentration threshold. No percentage of total alkaloids. No exemption for natural leaf, and no separate treatment for the three lab-altered derivatives DPH went to the trouble of naming. That describes the published position rather than every line of the regulation, and the distinction is worth keeping. If a threshold or exemption sits inside the instrument, the department has not said so anywhere we can find.

That is the paradox at the centre of this order. The state's own kratom page makes exactly the distinction the industry has been asking regulators to make for two years: leaf contains trace 7-OH, the potent material is lab-altered, and the three derivatives are named by their chemical names. The order it supports is summarised as covering all forms, which puts a bag of leaf powder and a synthetic fluorinated derivative into the same legal box.

A threshold rule creates an incentive to reformulate. A categorical rule removes that lever, because no formulation change and no better certificate gets a product back into the state. The practical result is simple. Inside Massachusetts, from 28 August 2026, a low-7-OH leaf product and a concentrated 7-OH isolate carry the same legal status. A brand telling a Massachusetts customer that its extract falls outside the order because its 7-OH content is low, or because it is not one of the four named compounds, is describing an exemption the state has not announced.

What this means for extracts, including ours

We sell concentrates. So let us be direct about the part that is uncomfortable for us.

Nothing in the King K range is exempt from the Massachusetts order. Not the liquid shots, not the tablets, not the energy shots. The order covers all forms of kratom, our products are kratom products, and a low number on a certificate of analysis does not create an exemption where the regulation provides none. If you are in Massachusetts, treat 28 August 2026 as the date our products stop being lawful to sell there. A vendor who says otherwise is not describing the position the state has published.

The wider lesson for anyone buying concentrates is what a certificate of analysis can and cannot do. It tells you what one laboratory measured in one batch, within the limits of the panel it ran, and ours are on our lab results page. It cannot tell you whether your state has decided to care about those numbers. Only one of those is chemistry. For the longer version, our guide to extract potency, ratios and the 21 line goes through what the numbers on a label mean and what they conceal.

What the state says about withdrawal

DPH expects the availability of all kratom products in Massachusetts to be disrupted, and it has put in writing what it expects to follow. The exact wording matters, so here it is: "people who regularly use these products are likely to experience opioid tolerance and withdrawal symptoms when they stop or reduce their use, including craving, nausea, diarrhea, muscle and head aches, sniffling, sneezing, sweating, and irritability."

Read "or reduce" carefully, because most coverage has dropped it. The department is saying that cutting down can bring the same symptoms as stopping. That is directly relevant to anyone planning to taper before 28 August 2026, and it is the reason to make that plan with a clinician rather than alone. Extract users have particular reason to take it seriously, because a concentrate delivers more alkaloid per serving than leaf does.

DPH's advice is to seek medical care or substance use treatment rather than manage it alone, and it cites studies finding that medications used for opioid use disorder, buprenorphine in particular, are effective for kratom use disorder. Kratom itself is not a treatment for opioid withdrawal or opioid use disorder; the medicines with an evidence base are buprenorphine, methadone and naltrexone.

We are not going to suggest anyone buy ahead of the date, because a supply cliff is not a sales event. On how shops will hear about this, the department's published wording is permissive and worth quoting exactly: "Local Boards of Health may notify Massachusetts retailers of this action and reinforce the dangers associated with the products. This notice may also highlight the new Schedule 1 classification under state law and the legal requirements regarding possession of Schedule 1 substances." Local boards of health, and may. Possession appears in that sentence, and nothing published spells out what it means for a personal supply, so that question goes to a lawyer licensed in Massachusetts.

Questions we get about 7-OH

Is 7-OH natural or synthetic?

Both, and that ambiguity is why the labelling on this category is such a mess. 7-OH occurs naturally in kratom leaf at trace levels, and it forms in the body from mitragynine. The 7-OH in a high-potency tablet is generally manufactured from mitragynine, which makes the finished product a semi-synthetic preparation whatever the front of the box says.

Does a mitragynine extract contain 7-OH?

Almost certainly, and not only at leaf levels. Concentrating an extract concentrates the 7-OH that came with the starting material, and mitragynine can oxidise into 7-OH during processing and storage, so the figure in a finished concentrate is not fixed by what the leaf started with. DEA states that "evidence suggests that commercially available products, including extracts and synthetic formulations, contain a significantly higher concentration of 7-hydroxymitragynine than what is found in botanical M. speciosa." The number should appear on a current certificate of analysis for the batch in your hand.

What are MP, MGM-15 and MGM-16?

Mitragynine pseudoindoxyl, dihydro-7-hydroxymitragynine and the compound DEA names 9-fluoro-dihydro-7-hydroxymitragynine, which DPH lists as 9-fluoro-7-hydroxymitragynine. DEA records MGM-15 and MGM-16 as compounds developed in 2014 as potent opioid agonists, and MP as a chemical rearrangement product of 7-OH first isolated in 1974. All three are named on the DPH kratom page alongside high-concentration 7-OH, and all three appear at 91 FR 40910.

Does the Massachusetts order cover 7-OH only, or all kratom?

All kratom. The state summarises the order as applying to all forms of kratom, and no separate 7-OH threshold has been announced. That is the difference between the Massachusetts order and every federal action on this molecule so far.

Is the Massachusetts order permanent?

No. It is a temporary emergency regulation that remains in effect for up to one year from 28 August 2026, which puts the argument about what replaces it inside the twelve months that follow.

What to do with all this

If you are in Massachusetts, the date is 28 August 2026 and the order applies to everything, including us. If you use daily, call 800-327-5050 or your own clinician before that date rather than after it. Do that knowing what the state has said, which is that reducing can bring the same symptoms as stopping.

If you are anywhere else, the takeaway is a habit rather than a fact. Read the operative text of any rule that touches this category, look for whether it names a threshold, and then read what that threshold applies to. The federal filing names 0.050 percentage of 7-OH on a dry weight basis, and the same 0.050 percentage weight by weight or 1.00 milligram per article for extracts, concentrates, processed edibles and pressed pills. A rule written around a concentration is a rule you can measure against. A rule written around a plant is not. Our range, with its batch certificates attached, is in the King K kratom collection.

This article is general information about chemistry and state regulation. It is not legal advice and not medical advice. Kratom law varies by state, county and city and is changing quickly; confirm the current rule with your state health department or a qualified attorney before acting. If you are experiencing dependence, withdrawal or a medical emergency, contact a healthcare provider, call the Massachusetts Substance Use Helpline on 800-327-5050, or call 911. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.